SCOPE2 Workshop delegates.

SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?

Posted on 26 April 2016 by Ruby Ray

SCOPE2 is a randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET). SCOPE2 is a Cancer Research UK funded trial run by the Wales Cancer Trials Unit based in the
Read more

PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer

Posted on 13 April 2016 by Joanna Canham

In 2013, there were 45,525 new cases of lung cancer in the UK and it kills around 35,000 annually (Source: CRUK). Non-small cell lung cancer (NSCLC) accounts for around 87% of all lung cancer. NSCLC is one of the leading causes of death worldwide and presents a huge health economic burden. The majority of patients
Read more

FRAGMATIC: Results of the Largest UK Trial of Lung Cancer Patients with Low Molecular Weight Heparin

Posted on 9 February 2016 by Richard Haggerty

The results of the Fragmatic trial were recently published in the Journal of Clinical Oncology. The trial was funded by Cancer Research UK with support from Pfizer to answer this question: ‘Should all newly diagnosed people with lung cancer be offered daily injections of a drug called dalteparin for six months to improve survival and
Read more